- Home
- IFS vs ACAD Comparison
IFS vs ACAD Comparison
Compare IFS & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IFS | ACAD |
|---|---|---|
| Founded | 1897 | 1993 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.2B |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | IFS | ACAD |
|---|---|---|
| Price | $39.84 | $27.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $29.24 |
| AVG Volume (30 Days) | 199.3K | ★ 1.5M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | 81.66 | ★ 98.53 |
| EPS | ★ 5.02 | 1.54 |
| Revenue | ★ $1,581,287,530.00 | $1,047,118,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | $3.48 | $11.42 |
| P/E Ratio | ★ $7.95 | $17.80 |
| Revenue Growth | ★ 33.10 | 12.69 |
| 52 Week Low | $27.97 | $13.40 |
| 52 Week High | $43.67 | $27.61 |
Technical Indicators
Market Signals| Indicator | IFS | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 76.30 |
| Support Level | $39.98 | $22.81 |
| Resistance Level | $41.23 | $25.20 |
| Average True Range (ATR) | 0.84 | 0.86 |
| MACD | 0.06 | 0.31 |
| Stochastic Oscillator | 52.72 | 96.35 |
Price Performance
Historical ComparisonAbout IFS Intercorp Financial Services Inc.
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.